What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Tisagenlecleucel demonstrated a clear clinical advantage with significant improvements in overall survival (OS) and event-free survival (EFS) compared to blinatumomab and salvage chemotherapy, as indicated by the matching-adjusted indirect comparison (MAIC) results. The hazard ratios suggest substantial benefits, although the evidence is primarily from single-arm studies rather than Phase 3 trials.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for tisagenlecleucel are within the acceptable range for Healthcare resources, with an ICER around £20,000 per QALY gained. This suggests it is marginally cost-effective, although the estimates carry some uncertainty.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that patients reported considerable improvements in quality of life following treatment with tisagenlecleucel, with manageable side effects. However, the data on HRQoL improvements were not extensively quantified using validated tools, leading to a moderate rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Tisagenlecleucel has a very good safety profile, with mostly manageable adverse events such as hypogammaglobulinaemia and cytokine release syndrome. The clinical expert noted that these side effects are less severe compared to those from traditional treatments like allo-SCT.
Was the drug compared against what payers expect? — Comparator Selection
The main comparators, blinatumomab and salvage chemotherapy, were appropriately selected. However, the absence of direct head-to-head trials limits the robustness of the evidence, necessitating reliance on indirect comparisons.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is largely representative of the intended patient population, with a focus on those aged 25 years and under. However, there are some limitations in subgroup analyses that could affect generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Tisagenlecleucel can be integrated into existing care pathways with minor adjustments, as it has been used in the Healthcare since 2018. The treatment does not require significant new infrastructure or training.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of tisagenlecleucel are manageable, with a cost structure that aligns with Healthcare planning. The treatment is expected to provide good value relative to its benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes multiple studies, although primarily from single-arm trials. The robustness is supported by real-world evidence, but the lack of Phase 3 trials introduces some methodological concerns.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding long-term outcomes and the effectiveness of comparators, the context of high unmet need and the potential for significant patient benefit mitigate these concerns.
